Erschienen in:
05.05.2017 | Side Effects of Endocrine Treatments
Oral mucositis induced by treatment with soft gel formulation of levothyroxine
verfasst von:
Erika Messina, Francesco Ferraù, Salvatore Cannavò
Erschienen in:
Endocrine
|
Ausgabe 1/2018
Einloggen, um Zugang zu erhalten
Excerpt
The development of the novel oral formulations of levothyroxine (LT4), i.e. liquid preparations and soft gel capsules, represents a remarkable innovation in the replacement therapy of hypothyroidism [
1,
2]. These new formulations are more effective than tablets in normalizing thyrotropin (TSH) levels in hypothyroid patients with intestinal malabsorption, gastric disorders, or ingesting drugs or food known to interfere with LT4 absorption [
2,
3]. Furthermore, the LT4 tablets need to be taken in a fasting state, while the new oral formulations can be directly ingested at breakfast, thus improving the therapeutic compliance. …